febuxostat + colchicine

Febuxostat + colchicine is a combination therapy used primarily in the management of gout. Febuxostat is a xanthine oxidase inhibitor that lowers uric acid levels by inhibiting the enzyme responsible for uric acid production, thereby preventing gout flares and long-term joint damage. Colchicine is an anti-inflammatory agent that disrupts microtubule formation, reducing neutrophil activity and inflammation during acute gout attacks or as prophylaxis when initiating urate-lowering therapy. This combination is often used to both lower serum urate (febuxostat) and prevent or treat acute flares (colchicine), especially during the initial phase of urate-lowering treatment[1][2][4][7]. Clinical studies indicate that this combination does not significantly increase hepatotoxicity compared to febuxostat alone, though caution should be exercised in patients with pre-existing liver disease[1][2]. Both drugs are approved for use in gout; febuxostat is typically reserved for patients who cannot tolerate allopurinol, while colchicine can be used for both treatment and prevention of flares.